Orion Pharma Ltd. is listed on the Dhaka Stock Exchange under the ticker ORIONPHARM. This page carries the price history chart for ORIONPHARM and lets you practice buying and selling it with virtual money, under the same trading hours, settlement delay and commission the real market applies.
Chart data is derived from the published Dhaka Stock Exchange day-end archive. It can lag or contain gaps and should never be treated as an official quote.
Audited financial ratios and DSE exchange disclosures for ORIONPHARM
Official Price Sensitive Information (PSI) and filings for ORIONPHARM
Hold ORIONPHARM in your portfolio?
Boss Tier subscribers get access to the Portfolio News Radar, automatically scanning all active holdings and highlighting critical dividend declarations and PSI updates.
Upgrade to Boss (৳20/mo)As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 09, 2026 at 4:00 PM to consider, among others, annual audited financial statements of the Company for the year ended June 30, 2026.
(Q3 Un-audited): Consolidated EPS was BDT (0.65) for January-March 2026 as against BDT 0.02 for January-March 2025; Consolidated EPS was BDT (0.95) for July 2025-March 2026 as against BDT (0.18) for July 2024-March 2025. Consolidated NOCFPS was BDT 4.06 for July 2025-March 2026 as against BDT 5.27 for July 2024-March 2025. (cont.) (cont. news of ORIONPHARM): Consolidated NAV per share (including revaluation surplus) was BDT 85.46 as on March 31, 2026, and BDT 86.09 as on June 30, 2025; consolidated NAV per share (excluding revaluation surplus) was BDT 77.72 as on March 31, 2026, and BDT 78.34 as on June 30, 2025. (end)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 29, 2026 at 4:00 pm to consider, among others, Un-Audited Financial Statements for the Third Quarter (Q3) period ended March 31, 2026.
(Q2 Un-audited): Consolidated EPS was Tk. (0.56) for October-December 2025 as against Tk. (0.44) for October-December 2024; Consolidated EPS was Tk. (0.86) for July-December 2025 as against Tk. (0.20) for July-December 2024. Consolidated NOCFPS was Tk. 2.61 for July-December 2025 as against Tk. 4.26 for July-December 2024. Consolidated NAV per share with revaluation surplus was Tk. 85.74 as on December 31, 2025 and Tk. 86.09 as on June 30, 2025. (cont.) (Cont. News of ORIONPHARM): Consolidated NAV per share without revaluation surplus was Tk. 78.00 as on December 31, 2025 and Tk. 78.34 as on June 30, 2025. (end)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 29, 2026 at 4:00 PM to consider, among others, Un-Audited Financial Statements for the Second Quarter (Q2) period ended December 31, 2025.
Credit Rating Agency of Bangladesh Limited (CRAB) has announced the surveillance entity rating of the Company as "A1" in the long term and "ST-4" in the short term along with Stable outlook based on audited financial statements (FYE 30/06/2025, 30/06/2024, 30/06/2023), bank liability as on 08/12/2025 and other information up to the date of rating declaration.
The auditor of the company has given the Qualified Opinion, Emphasis of Matter and Other Matter paragraph in the audited financial statements of the company for the year ended June 30, 2025. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2025/ORIONPHARM_2025.pdf
Refer to their earlier news disseminated by DSE on 12.11.2025 regarding dividend declaration & EGM for Related Party Transactions and company name change, the company has further informed that due to unavoidable circumstances, the venue of the forthcoming AGM and EGM has been changed to " Extended Corporate Office: (3rd Floor) 1327 Tejgaon Industrial Area, Dhaka-1208" from " Orion House, 153-154 Tejgaon Industrial Area, Dhaka-1208". (cont.) (Cont. News of ORIONPHARM): It is to be noted that all other information relating to the AGM and EGM, including the date, time, and agenda, shall remain unchanged. (end)
Trading of the shares of the company will resume on 07.12.2025.
Trading of the shares of the company will remain suspended on record date i.e., 04.12.2025 for AGM and EGM.
Nothing is loosened to make practice easier. An order for ORIONPHARM is accepted only while the Dhaka Stock Exchange is open, commission is deducted the way a broker would deduct it, and shares cannot be sold until they have settled: two trading days after purchase for categories A, B, G and N, three for category Z.
This is an ordinary equity listing on the Dhaka Stock Exchange. Buying a share means owning a small stake in the business, and the share price responds to earnings, dividends, sector conditions and overall market sentiment.
Ordinary shares are the most straightforward instrument to learn on, which is why most people start here before touching funds or bonds.
Audited financial ratios, annual EPS, NAVPS, 52-week price range and dividend history for ORIONPHARM are published above. For external community discussions or alternative screener tools, you can also inspect ORIONPHARM on third-party market sites.
We do not use StockNow data, and this link is neither sponsored nor affiliated.
View ORIONPHARM on StockNowWe are not responsible for the content of that site or for anything you do there.
Test an idea on ORIONPHARM with virtual money in the full trading terminal, alongside the rest of your practice portfolio.
Open the trading terminalOrion Pharma Ltd. trades on the Dhaka Stock Exchange under the ticker ORIONPHARM (PharmaChem sector, Category Z, listed in 2013). You use that symbol to look the company up on the exchange, with a broker, or inside the StockSimulatorBD practice terminal.
According to Dhaka Stock Exchange disclosures published on this StockSimulatorBD page, ORIONPHARM has a reference share price of ৳25.3, audited P/E ratio of 0.00, annual EPS of ৳-1.77, NAVPS (book value) of ৳86.09, dividend yield of 0.00%, 52-week trading range of ৳22.9 to ৳33.2. In 2025, ORIONPHARM declared no dividend.
Yes. StockSimulatorBD lets you buy and sell ORIONPHARM using a virtual balance. Orders follow the same rules the real market applies, including authentic DSE trading hours (10:00 to 14:15 BST), T+2/T+3 settlement lots (by market category) and a 0.40% commission, but no real money is ever involved and the balance cannot be withdrawn.
No. A BO (Beneficiary Owner) account with a licensed broker is required to buy ORIONPHARM for real on the Dhaka Stock Exchange, but not to practice on StockSimulatorBD. Many investors audit company fundamentals and rehearse trades here before opening a broker account.
The Dhaka Stock Exchange trades Sunday to Thursday from 10:00 to 14:15 Bangladesh Standard Time (BST) and is closed on Friday, Saturday and public holidays. The simulator enforces the same schedule, so ORIONPHARM orders are only accepted while the real market is open.